TheraCryf: Initiation - Strong Healing
TheraCryf is a clinical stage drug development company focused on commercialising its proprietary formulation of sulforaphane, SFX-01, and two novel drug candidates acquired in the recent Chronos transaction. The primary targets for SFX-01 are cancer and neurodevelopmental disorders while TheraCryf's new orexin and DAT programmes, extend the company's reach into neuropsychiatric drugs, currently a very active area for acquisitions and partnering. Potential target markets total in the billions of dollars. The company has multiple academic collaborations and a partnership with Stalicla potentially worth up to US$161m in milestone payments. The company has a financial runway through towards the end of FY26. Despite its advantages, TheraCryf trades on a fraction of the rating of peers with similar characteristics and has multiple prospective newsflow events due in 2024/25.Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.